Completed PHASE2 INTERVENTIONAL NCT00001407

Interferon Gamma for Drug Resistant Tuberculosis

Treatment of Multiply Drug Resistant Tuberculosis With Interferon Gamma: A Phase I/II Dose Escalation Trial

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Pneumonia Pulmonary Tuberculosis

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: May 31, 1994 Completion: May 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pneumonia and Pulmonary Tuberculosis and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 5 recorded versions since 1994 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States